Human Papillomavirus Hpv clinical trials

Explore recruiting human papillomavirus hpv clinical trials.

Recruiting human papillomavirus hpv studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Human Papillomavirus Hpv trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age

Germany, Czechia, Italy, France, Belgium, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Primary chemoradiation versus neoadjuvant chemotherapy followed by surgery as treatment strategy for locally advanced vulvar carcinoma (VULCANize2)

Netherlands, Belgium, Czechia, Spain

Phase II and Phase III (Integrated) EU CTIS Study details

A Registry-Based Extension of Protocol V503-001 in Countries with Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine as Administered to 16- to 26- Year- Old Women.

Norway, Sweden, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Vaccination against human papillomavirus (HPV) after allogeneic stem cell transplantation, a randomized study between early and late vaccination.

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

PATHOS : A Phase III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer

France, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multicentric randomized phase I/IIa trial of the safety and immunogenicity of a therapeutic HPV DC targeting vaccine in patients with Human papillomavirus (HPV)-positive oropharyngeal cancer (HPV.DCVax)

France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Human Papillomavirus Hpv trials by city

Human Papillomavirus Hpv in Toronto Human Papillomavirus Hpv in Vancouver Human Papillomavirus Hpv in Montreal Human Papillomavirus Hpv in Calgary Human Papillomavirus Hpv in Edmonton Human Papillomavirus Hpv in Ottawa Human Papillomavirus Hpv in Winnipeg Human Papillomavirus Hpv in Quebec City Human Papillomavirus Hpv in Hamilton Human Papillomavirus Hpv in Kitchener Human Papillomavirus Hpv in London Human Papillomavirus Hpv in Halifax Human Papillomavirus Hpv in New York Human Papillomavirus Hpv in Los Angeles Human Papillomavirus Hpv in Chicago Human Papillomavirus Hpv in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease